How effective is Guanfacine?

Guanfacine has been extensively studied and shown to be effective in treating attention deficit hyperactivity disorder (ADHD). Multiple clinical studies have shown that guanfacine can significantly improve ADHD symptom scores in children and adolescents, specifically in areas such as concentration, impulse control, and hyperactivity.

In one study of 337 children aged 6 to 17 years, after 10 to 13 weeks of guanfacine treatment, participants experienced a 24-point reduction in ADHD symptom scores, compared with only a 15-point reduction in those who received a placebo. In addition, patients who took atomoxetine, a common ADHD drug, only experienced a 19-point reduction in symptom scores. This suggests that guanfacine is better than placebo in improving ADHD symptoms and is more effective than other medications.

Another study of 312 adolescents aged 13 to 17 years further confirmed this result. After 13 weeks of treatment, ADHD scores decreased by 25 points in the guanfacine group and by 19 points in the placebo group. These data not only highlight the potential of guanfacine as a treatment for ADHD, but also show that it can produce positive therapeutic effects in patients of all ages.

The long-term effects of guanfacine were also considered by assessing the proportion of treatment failures. In a long-term maintenance study of 301 children and adolescents aged 6 to 17 years, 49% of guanfacine patients experienced treatment failure, compared with 65% of patients receiving placebo. This suggests that guanfacine is excellent at maintaining treatment effects and can help patients better manage ADHD symptoms.

Overall, the results of studies of guanfacine in improvingADHD symptoms indicate that it is an effective treatment option, allowing patients to experience better attention and behavioral control in their daily lives. While each patient's response may vary, substantial clinical data support its use in children and adolescents.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv